Heterogeneity in ME/CFS

Last week, in a posting on X, the Simmaron Research Centre, USA (whose institute works to advance translational science in treating neuroimmune diseases) have highlighted that “one of the biggest challenges in ME/CFS research has been patient heterogeneity“. This research group is behind a Rapamycin Pilot Treatment Trial for ME/CFS, and in 2022 published a […]